Merck Sharp & Dohme LLC acquires Cidara Therapeutics, Inc. (2026)

Deal facts

Buyer: Merck Sharp & Dohme LLC
Target: Cidara Therapeutics, Inc.
Deal value: Not disclosed
Announced: 7 January 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

7 Jan 2026CompletedClosed
Merck Sharp & Dohme LLC completes acquisition of Cidara Therapeutics, Inc.
Introductory Note. As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission (“ SEC ”) by Cidara Therapeutics, Inc., a Delaware corporation (the “ Company ”) on November 14, 2025, the Company entered into an Agreement and Plan of Merger, dated November 13, 2025 (the “ Merger Agreement ”), with Merck Sharp & Dohme LLC, a New Jersey limited liability
Source

OpinionExit Mode editorial

We see a clear signal in the recent announcement that Parent has acquired Cidara Therapeutics, Inc. The deal, which closed on 7 January 2026, marks a definitive shift from public markets to private ownership. This going-private transaction in the US healthcare sector is structured entirely as a cash consideration. The absence of any disclosed value or currency figures in the public record is notable, yet the mechanics are straightforward. The target company has ceased to be a listed entity, removing the daily volatility and quarterly reporting burdens that often distract from long-term scientific development.

For the SME founder watching from the other side of the Atlantic, this move highlights the growing pressure on smaller biotech firms to find a home before their cash runway expires. The decision to go private via a full cash exit suggests the buyer values control and speed over the complexity of a share-swap or a staged rollout. In the current regulatory climate, a clean cash deal avoids the protracted shareholder votes and prospectus filings that can derail a public-to-private conversion. It also sidesteps the potential for hostile activist intervention, which frequently plagues life sciences companies with high burn rates and no immediate revenue. The buyer has effectively purchased the entire equity stake, eliminating minority shareholder friction and allowing for immediate strategic realignment.

The speed of completion implies that due diligence was thorough and that the buyer was prepared to act decisively. We note that the deal type specifically removes the target from public scrutiny, which can be a double-edged sword. While it grants management the freedom to execute a longer-term vision without market interference, it also means the founder and team must now answer to a single owner rather than a dispersed group of investors. This concentration of power demands a robust governance framework and clear exit covenants for any remaining management equity. The risk of a change-of-control clause being triggered in existing vendor agreements or licensing deals must have been a primary focus during the negotiation phase.

You should review your own shareholder agreement this week to identify any change-of-control triggers that could force an immediate sale or repayment of debt if you ever receive a similar offer.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More going private deals More from Merck Sharp & Dohme LLC All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

27 April 2026CompletedHealthcare

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. entered the Exit Mode archive.

Buyer: BioMarin Pharmaceutical Inc.
Target: Amicus Therapeutics, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 April 2026CompletedHealthcare

Servier to acquire Day One Biopharmaceuticals, Inc.

Servier and Day One Biopharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Servier
Target: Day One Biopharmaceuticals, Inc.
Deal value: USD 2,500,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 March 2026CompletedHealthcare

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. entered the Exit Mode archive.

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 March 2026CompletedHealthcare

Abbott to acquire Exact Sciences Corp

Abbott and Exact Sciences Corp entered the Exit Mode archive.

Buyer: Abbott
Target: Exact Sciences Corp
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history